Praxis receives FDA alignment on ulixacaltamide NDA submission plans
Go back to Praxis receives FDA alignment on ulixacaltamide NDA submission plans| (NASDAQ: PRAX) | Delayed: 300.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $300.65 | 52 Week High | $ | |||
| Open | $300.65 | 52 Week Low | $ | |||
| Day High | $300.65 | P/E | N/A | |||
| Day Low | $300.65 | EPS | $ | |||
| Volume | 3 | |||||
